Candel Therapeutics, Inc. $CADL Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. grew its holdings in Candel Therapeutics, Inc. (NASDAQ:CADL) by 60.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 83,880 shares of the company’s stock after purchasing an additional 31,690 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.17% of Candel Therapeutics worth $474,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. BNP Paribas Financial Markets purchased a new position in Candel Therapeutics during the fourth quarter worth approximately $30,000. Private Advisor Group LLC acquired a new stake in Candel Therapeutics during the 1st quarter valued at $58,000. Wells Fargo & Company MN grew its holdings in Candel Therapeutics by 63.6% during the 4th quarter. Wells Fargo & Company MN now owns 10,122 shares of the company’s stock valued at $88,000 after purchasing an additional 3,935 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Candel Therapeutics by 12.4% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,165 shares of the company’s stock worth $106,000 after acquiring an additional 1,340 shares in the last quarter. Finally, Janney Montgomery Scott LLC lifted its position in shares of Candel Therapeutics by 104.3% in the 1st quarter. Janney Montgomery Scott LLC now owns 21,090 shares of the company’s stock worth $119,000 after buying an additional 10,765 shares during the last quarter. Hedge funds and other institutional investors own 13.93% of the company’s stock.

Candel Therapeutics Trading Down 12.8%

Shares of CADL stock opened at $5.11 on Thursday. The firm has a fifty day moving average of $5.99 and a 200-day moving average of $6.16. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.04 and a current ratio of 7.04. Candel Therapeutics, Inc. has a 52-week low of $3.79 and a 52-week high of $14.60. The stock has a market cap of $280.54 million, a price-to-earnings ratio of -7.41 and a beta of -0.90.

Candel Therapeutics (NASDAQ:CADL) last posted its earnings results on Thursday, August 14th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.08. On average, equities research analysts forecast that Candel Therapeutics, Inc. will post -1.47 earnings per share for the current fiscal year.

Analysts Set New Price Targets

CADL has been the topic of several recent research reports. Bank of America downgraded shares of Candel Therapeutics from a “buy” rating to a “neutral” rating and cut their price objective for the company from $13.00 to $7.00 in a research report on Wednesday. Brookline Capital Management raised shares of Candel Therapeutics to a “strong-buy” rating in a research note on Wednesday, July 9th. Wall Street Zen raised shares of Candel Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, May 22nd. Finally, HC Wainwright raised shares of Candel Therapeutics to a “buy” rating and set a $23.00 price objective on the stock in a research report on Monday, June 30th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $20.00.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.